Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 3 for:    Geraniol

A Nicotine Pharmacokinetics and Smoking Behaviour Study Examining Cigarette Ingredients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03272295
Recruitment Status : Not yet recruiting
First Posted : September 5, 2017
Last Update Posted : September 5, 2017
Sponsor:
Collaborators:
Philip Morris Products S.A.
Imperial Tobacco Group PLC
Japan Tobacco Inc.
Korea Ginseng Corporation
Information provided by (Responsible Party):
British American Tobacco (Investments) Limited

Tracking Information
First Submitted Date  ICMJE August 15, 2017
First Posted Date  ICMJE September 5, 2017
Last Update Posted Date September 5, 2017
Estimated Study Start Date  ICMJE September 12, 2017
Estimated Primary Completion Date December 1, 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 31, 2017)
Cmax [ Time Frame: -5, 1, 2, 3, 4, 5, 6, 7, 8, 15, 60, 120, 180 and 240 minutes in relation to the first puff ]
To assess the maximum nicotine concentration when subjects smoke a single cigarette
Original Primary Outcome Measures  ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures  ICMJE
 (submitted: August 31, 2017)
  • AUC0-last [ Time Frame: -5, 1, 2, 3, 4, 5, 6, 7, 8, 15, 60, 120, 180 and 240 minutes in relation to the first puff ]
    To assess the area under the concentration curve from time 0 to last the time-point when subjects smoke a single cigarette
  • Tmax [ Time Frame: -5, 1, 2, 3, 4, 5, 6, 7, 8, 15, 60, 120, 180 and 240 minutes in relation to the first puff ]
    To assess the time to maximum nicotine concentration when subjects smoke a single cigarette
  • Puff Volume [ Time Frame: During the time required to smoke a single cigarette (up to 8 minutes) ]
    To assess puff volume when subjects smoke a single cigarette
  • Puff duration [ Time Frame: During the time required to smoke a single cigarette (up to 8 minutes) ]
    To assess puff duration when subjects smoke a single cigarette
  • Number of puffs [ Time Frame: During the time required to smoke a single cigarette (up to 8 minutes) ]
    To assess number of puffs when subjects smoke a single cigarette
  • Inhalation volume [ Time Frame: During the time required to smoke a single cigarette (up to 8 minutes) ]
    To assess inhalation volume when subjects smoke a single cigarette
  • Exhalation volume [ Time Frame: During the time required to smoke a single cigarette (up to 8 minutes) ]
    To assess exhalation volume when subjects smoke a single cigarette
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Nicotine Pharmacokinetics and Smoking Behaviour Study Examining Cigarette Ingredients
Official Title  ICMJE A Randomised, Controlled, Double-Blind Study to Examine Nicotine Pharmacokinetics and Smoking Behaviour in Healthy Smokers When Smoking Cigarettes Containing Different Commonly Used Ingredients
Brief Summary This study will compare nicotine delivery and smoking behaviour in healthy subjects using several combustible cigarette prototypes containing different ingredients which are commonly used in the European Union.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Masking Description:
A double-blind study in respect of the site (except pharmacy) and subjects.
Primary Purpose: Other
Condition  ICMJE
  • Healthy Volunteers
  • Smoking
Intervention  ICMJE
  • Other: Reference cigarette
    The reference product is based on a commercially-available king-size cigarette design (length 83 mm, circumference 24.6 mm) with a single segment cellulose acetate filter and tobacco blend recipe without ingredients.
  • Other: Cigarette with carob bean extract
    Based on reference cigarette with added ingredient
  • Other: Cigarette with cocoa powder
    Based on reference cigarette with added ingredient
  • Other: Cigarette with fenugreek extract
    Based on reference cigarette with added ingredient
  • Other: Cigarette with fig juice
    Based on reference cigarette with added ingredient
  • Other: Cigarette with glycerol
    Based on reference cigarette with added ingredient
  • Other: Cigarette with guaiacol
    Based on reference cigarette with added ingredient
  • Other: Cigarette with liquorice extract powder
    Based on reference cigarette with added ingredient
  • Other: Cigarette plus I-menthol
    Based on reference cigarette with added ingredient
  • Other: Cigarette with propylene glycol
    Based on reference cigarette with added ingredient
  • Other: Cigarette with sorbitol
    Based on reference cigarette with added ingredient
  • Other: Cigarette with multiple ingredients
    Based on reference cigarette plus propylene glycol, glycerol, liquorice extract powder, cocoa powder, carob bean extract, fig juice concentrate, maltol, guaiacol, geraniol, fenugreek extract.
Study Arms  ICMJE
  • Experimental: Arm A
    Reference product (product 1) x 2, Single ingredients products 2, 3, 4, 5, 6 and Multiple ingredient product (product 12). Single cigarette each for nicotine PK assessment and smoking behaviour assessment.
    Interventions:
    • Other: Reference cigarette
    • Other: Cigarette with carob bean extract
    • Other: Cigarette with cocoa powder
    • Other: Cigarette with fenugreek extract
    • Other: Cigarette with fig juice
    • Other: Cigarette with glycerol
    • Other: Cigarette with multiple ingredients
  • Experimental: Arm B
    Reference product (product 1), Single ingredients products 7, 8, 9, 10, 11 and Multiple ingredient product (product 12). Single cigarette each for nicotine PK assessment and smoking behaviour assessment.
    Interventions:
    • Other: Reference cigarette
    • Other: Cigarette with guaiacol
    • Other: Cigarette with liquorice extract powder
    • Other: Cigarette plus I-menthol
    • Other: Cigarette with propylene glycol
    • Other: Cigarette with sorbitol
    • Other: Cigarette with multiple ingredients
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: August 31, 2017)
48
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 1, 2017
Estimated Primary Completion Date December 1, 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Subjects will be:

    1.1. males or females 1.2. 21 to 55 years of age, inclusive, demonstrated by appropriate proof of identification.

  2. Subjects will have a:

    2.1. BMI of 18.5 to 30.0 kg/m2, inclusive 2.2. body weight exceeding 52 kg (males) or 45 kg (females)

  3. Subjects will be in good health, as judged by the PI or the appropriately qualified designee based on:

    3.1. medical history 3.2. physical examination 3.3. vital signs assessment 3.4. 12-lead ECG 3.5. clinical laboratory evaluations 3.6. lung function tests

  4. Subjects will have given their written informed consent to participate in the study and will have agreed to abide by the study restrictions.
  5. Subjects must demonstrate the ability to comprehend the informed consent form (ICF), be able to communicate well with the PI or the appropriately qualified designee, understand and comply with the requirements of the study, and be judged suitable for the study in the opinion of the PI or the appropriately qualified designee.
  6. Subjects will be willing to refrain from consuming alcohol within 24 hours prior to Admission.
  7. Subjects will be regular smokers of factory made, non-menthol cigarettes whose chosen brand is within the ISO tar bands 6 to 10 mg, inclusive and should not change their usual brand cigarette for the duration of the study.
  8. Subjects will have smoked their chosen brand for a minimum of 6 months and will have smoked for at least 3 years prior to Screening, and will typically smoke at least 10 and a maximum of 30 CPD.
  9. Subjects must have a urine cotinine level >200 ng/mL and an ECO measurement of >10 ppm at Screening.
  10. Subjects will be willing to use the study products and smoke only the study products provided to them during clinical confinement and to abstain from smoking when required.

Exclusion Criteria:

  1. Male subjects who do not agree, or whose partners of childbearing potential do not agree, to use a barrier method of contraception (i.e., a condom with spermicide) in addition to a second highly effective method of contraception used by their female partners or to refrain from donating sperm from Admission for Visit 1 until 5-7 days after Discharge.
  2. Female subjects of childbearing potential who do not agree to use a highly effective method of birth control in conjunction with male barrier method contraception (i.e., a condom with spermicide) from the time of signing the ICF until 5-7 days after Discharge.
  3. Female subjects who are pregnant or breastfeeding. This will be confirmed at Screening and at each Admission. Any female subject who becomes pregnant during this study will be withdrawn.
  4. Subjects who have donated:

    4.1. ≥450 mL of blood within 90 days prior to Admission 4.2. plasma in the 7 days prior to Admission 4.3. platelets in the 6 weeks prior to Admission

  5. Subjects who have an acute illness (e.g., upper respiratory tract infection, viral infection, etc.) requiring treatment within 4 weeks prior to Admission.
  6. Subjects who have used any nicotine or tobacco product other than commercially manufactured non-menthol, filter cigarettes within 14 days of Screening.
  7. Subjects who are self-reported non-inhalers (smokers who draw smoke from the cigarette into the mouth and throat but who do not inhale). Subjects who are determined as non-inhalers at Screening will be excluded.
  8. Subjects who, prior to enrolment, are planning to quit smoking in the next 12 months of Screening. All subjects will be informed that they are free to quit smoking and withdraw from the study at any time. Any subject who decides to quit smoking will be directed to appropriate stop smoking services
  9. Subjects who have a significant history of alcoholism or drug/chemical abuse within 24 months prior to Screening, as determined by the PI or the appropriately qualified designee.
  10. Subjects who have a positive urine drugs of abuse or alcohol screen (confirmed by repeat) at Screening or Admission.
  11. Subjects who:

    11.1. have serum hepatitis 11.2. are carriers of the hepatitis B surface antigen (HBsAg) 11.3. are carriers of the hepatitis C antibody 11.4. have a positive result for the test for human immunodeficiency virus (HIV) antibodies.

  12. Subjects who have used prescription or OTC bronchodilator medication (e.g., inhaled or oral β-adrenergic agonists) to treat a chronic condition within the 12 months prior to the first Admission (Visit 1) and throughout the study.
  13. Subjects who have received any medications or substances (other than tobacco) which:

    13.1. are known to be strong inducers or inhibitors of CYP enzymes within 14 days or 5 half-lives of the drug (whichever is longer) prior to the first Admission (Visit 1) and throughout the study.

  14. Subjects who are planning to undergo significant lifestyle changes during the study e.g., big change in exercise levels.
  15. Subjects who are unable to communicate effectively with the PI/study staff (i.e., language problem, poor mental development, or impaired cerebral function).
  16. Subjects who are unwilling or unable to comply with the study requirements.
  17. Employees, and immediate relatives, of the tobacco industry or the clinical site.
  18. Subjects who are still participating in another clinical study (e.g., attending follow-up visits) or who have participated in a clinical study involving administration of an investigational drug (new chemical entity) in the past 3 months prior to first Admission (Visit 1).
  19. Subjects who have any clinically relevant abnormal findings on the physical examination, medical history, ECG, lung function tests (forced expiratory volume in 1 second/ forced vital capacity [FEV1/FVC]), or clinical laboratory panel, unless deemed not clinically significant by the PI or the appropriately qualified designee.
  20. Subjects who have, or who have had a history of, any clinically significant neurological, gastrointestinal, renal (including urinary tract infection or nephrolithiasis), hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine, haematological or other major disorder that, in the opinion of the PI or the appropriately qualified designee, would jeopardise the safety of the subject or impact on the validity of the study results.
  21. Subjects who have previously been diagnosed with any form of malignancy.
  22. Subjects who have any clinically significant abnormal laboratory safety findings at Screening and prior to first product use, as determined by the PI or the appropriately qualified designee (1 repeat assessment is acceptable).
  23. Subjects who have previously been randomised into or withdrawn from this study.
  24. Subjects who, in the opinion of the PI or the appropriately qualified designee, should not participate in this study.

Compliance with all inclusion and exclusion criteria will be reaffirmed at each study Visit.

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 21 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Ian M Fearon, PhD +44 (0) 2380 588641 ian_fearon@bat.com
Contact: Alison C Eldridge, HNC +44 (0) 2380 793499 alison_eldridge@bat.com
Listed Location Countries  ICMJE United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03272295
Other Study ID Numbers  ICMJE BAT1117009
CA21208 ( Other Identifier: Celerion GB Ltd )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party British American Tobacco (Investments) Limited
Study Sponsor  ICMJE British American Tobacco (Investments) Limited
Collaborators  ICMJE
  • Philip Morris Products S.A.
  • Imperial Tobacco Group PLC
  • Japan Tobacco Inc.
  • Korea Ginseng Corporation
Investigators  ICMJE
Principal Investigator: Johnston Stewart, MB Celerion GB Ltd
PRS Account British American Tobacco (Investments) Limited
Verification Date August 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP